SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CYBN

Cybin Inc. (New York Stock Exchange Arca:CYBN)

CA · Delayed Price · Currency is USD
Also listed: CYBN.NEHealthcare · Biotechnology
$8.28+$0.10 (+1.22%)
 
Market cap
$413M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 13, 2019
Website
Market Cap$413.02M-15.8%
Revenue (ttm)$0
Net Income-$92.91M+24.9%
EPS-$4.17-23.0%
Shares Out49.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume716,528
Open$8.28
Previous Close$8.18
Day's Range$8.14 - $8.38
52-Week Range$4.81 - $10.72
Beta0.79
AnalystsBuy
Price Targetn/a
Earnings Daten/a
No price history available.

About CYBN

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Address
100 King Street West, Toronto, ON, M5X 1C9, CA
Market Cap
413 million
Employees
50
Industrial Classification
Biotechnology

Cybin Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
87th Percentile Overall Score
CYBN InsiderScore:90 / 99

Cybin Inc. scored higher than 87% of companies evaluated by InsiderBuying, and ranked 12th out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Cybin Inc. bought $9.67 million of stock across 9 purchases in the last 90 days, the largest of them $1.35 million.

Stake Increase

The average purchase added about 19% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$9.67M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$5.07$7.11$9.15Dec
Financial Health Score
Fair
From CYBN’s reported statements · Q3 2025 (trailing 12 months) · 4 of 5 pillars
1 Day
+22.30%
5 Days
+10.40%
1 Month
+0.00%
6 Months
+9.52%
1 Year
-15.85%

$CYBN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CYBN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CYBN's directors and management

Net Shares Purchased by Insiders−800k−400k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CYBN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CYBN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CYBN from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from CYBN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
91.39
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
9
Sells
0
Buy Value
$9.67M
Distinct Buyers
4

Insider Score Trend Over Time

-5.9 since Sep 24
0255075100Sep 24 — Insider Score 95.6Sep 25 — Insider Score 97.1Sep 26 — Insider Score 97.1Sep 27 — Insider Score 97.1Sep 28 — Insider Score 97.1Sep 29 — Insider Score 97.0Sep 30 — Insider Score 96.9Oct 1 — Insider Score 96.6Oct 2 — Insider Score 57.0Oct 3 — Insider Score 96.5Oct 4 — Insider Score 97.7Oct 5 — Insider Score 97.7Oct 6 — Insider Score 97.6Oct 7 — Insider Score 97.5Oct 8 — Insider Score 97.5Oct 9 — Insider Score 97.4Oct 10 — Insider Score 97.3Oct 11 — Insider Score 97.4Oct 12 — Insider Score 97.4Oct 13 — Insider Score 97.4Oct 14 — Insider Score 97.3Oct 15 — Insider Score 97.3Oct 16 — Insider Score 97.2Oct 17 — Insider Score 97.2Oct 18 — Insider Score 97.2Oct 19 — Insider Score 97.2Oct 20 — Insider Score 97.2Oct 21 — Insider Score 97.3Oct 22 — Insider Score 97.2Oct 23 — Insider Score 97.2Oct 24 — Insider Score 97.2Oct 25 — Insider Score 97.1Oct 26 — Insider Score 97.2Oct 27 — Insider Score 97.2Oct 28 — Insider Score 97.2Oct 29 — Insider Score 97.3Oct 30 — Insider Score 97.0Oct 31 — Insider Score 97.0Nov 1 — Insider Score 96.8Nov 2 — Insider Score 96.8Nov 3 — Insider Score 96.6Nov 4 — Insider Score 96.4Nov 5 — Insider Score 96.1Nov 6 — Insider Score 95.8Nov 7 — Insider Score 95.8Nov 8 — Insider Score 95.9Nov 9 — Insider Score 95.9Nov 10 — Insider Score 95.5Nov 11 — Insider Score 95.2Nov 12 — Insider Score 94.9Nov 13 — Insider Score 94.4Nov 14 — Insider Score 93.8Nov 15 — Insider Score 94.0Nov 16 — Insider Score 93.8Nov 17 — Insider Score 93.2Nov 18 — Insider Score 92.1Nov 19 — Insider Score 91.0Nov 20 — Insider Score 90.4Nov 21 — Insider Score 89.5Nov 22 — Insider Score 89.7Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.